Abstract：In 2017, the US-FDA approved forty-six new drugs listed, including four antibacterial drugs and three antiviral drugs. This article is based on the FDA approved new drug specification and related literatures and patents, a brief description of delafloxacin, compound meropenem, secnidazole, ozenoxacin, and three anti-HCV drugs, vosevi, mavyret and letermovir, including research overview, routes of synthesis, indications, mechanism of action, dosage form specifications, and adverse reactions. Strictly speaking, secnidazole is a generic drug that has been listed for nearly thirty years in Europe and more than ten years in China.
